Abstract:Abstract Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality, underscores the urgent need for enhanced insights into the molecular and cellular mechanisms underlying metastasis, chemoresistance, and the mechanistic backgrounds of individuals whose cancers are prone to migration. The most prevalent signaling cascade governed by multi-kinase inhibitors is the mitogen-activated protein kinase (MAPK) pathway, encompassing the RAS–RAF–MAPK kinase (MEK)–extracellular signal-related kinase (ERK) pathway. RAF kinase is a primary mediator of the MAPK pathway, responsible for the sequential activation of downstream targets, such as MEK and the transcription factor ERK, which control numerous cellular and physiological processes, including organism development, cell cycle control, cell proliferation and differentiation, cell survival, and death. Defects in this signaling cascade are associated with diseases such as cancer. RAF inhibitors (RAFi) combined with MEK blockers represent an FDA-approved therapeutic strategy for numerous RAF -mutant cancers, including melanoma, non-small cell lung carcinoma, and thyroid cancer. However, the development of therapy resistance by cancer cells remains an important barrier. Autophagy, an intracellular lysosome-dependent catabolic recycling process, plays a critical role in the development of RAFi resistance in cancer. Thus, targeting RAF and autophagy could be novel treatment strategies for RAF -mutant cancers. In this review, we delve deeper into the mechanistic insights surrounding RAF kinase signaling in tumorigenesis and RAFi-resistance. Furthermore, we explore and discuss the ongoing development of next-generation RAF inhibitors with enhanced therapeutic profiles. Additionally, this review sheds light on the functional interplay between RAF-targeted therapies and autophagy in cancer.

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

The MEK/ERK Network as a Therapeutic Target in Human Cancer

The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

RAF-MEK-ERK pathway in cancer evolution and treatment

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

Targeting the RAF–MEK–ERK pathway in cancer therapy

Targeting RAS–ERK signalling in cancer: promises and challenges

Targeting RAS-RAF-MEK-ERK Signaling Pathway in Human Cancer: Current Status in Clinical Trials.

Extracellular-signal-regulated kinase/mitogen-activated protein kinase signaling as a target for cancer therapy: an updated review

Targeting Extracellular Signal-Regulated Protein Kinase 1/2 (ERK1/2) in Cancer: an Update on Pharmacological Small-Molecule Inhibitors.

Targeting the ERK signaling pathway in cancer therapy

ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

ERK/MAPK signalling pathway and tumorigenesis

Developments in Mitogen-Induced Extracellular Kinase 1 Inhibitors and Their Use in the Treatment of Disease

Targeting the RAS upstream and downstream signaling pathway for cancer treatment

ERK/MAPK Signalling Pathway and Tumorigenesis (Review)